Anti-Human IL6R Recombinant Antibody(Satralizumab)
-
产品编号
YR1396
-
别名
科研级 Satralizumab ( 萨特利珠单抗, 沙利珠单抗 ), Anti-IL6R Recombinant Antibody, Research Grade Satralizumab
-
规格
- 1mg
- 5mg
| Catalog Number | YR1396 |
| Alias | 科研级 Satralizumab ( 萨特利珠单抗, 沙利珠单抗 ), Anti-IL6R Recombinant Antibody, Research Grade Satralizumab |
| Size | 1mg, 5mg |
| Molecular Name | Satralizumab |
| CAS Number | 1535963-91-7 |
| Target | IL6R[Homo sapiens] |
| Antibody Isotype | IgG2 Kappa |
| Clonity | Monoclonal |
| Concentration | 1mg/ml |
| Purity | >95% as determined by SDS-PAGE |
| Storage Condition | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
| Formulation | PBS, pH7.5 |
| Shipping Condition | Shipped on ice packs. |
| Background | Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche. |
| Remarks | This product is for research use only. |
0